



The 4Tech TriCinch™ System for Transcatheter Tricuspid Valve Repair (TTVR)

What's the "next big thing in the cath lab" now that aortic and mitral heart valves can be repaired or replaced non-surgically?


Tricuspid Regurgitation (TR) afflicts more than 3 million patients in the United States and Europe, thus making the TR patient population about 2/3 of the size of the MR (Mitral Regurgitation) patient population. Nonetheless, **Tricuspid is The Forgotten Valve.**

Today's standard of care for TR is medical management. Surgical intervention is very high risk. In fact, in-hospital death post-cardiac surgery for isolated TR can be as high as 37%. (Source: McCarthy et al. *Journal of Thoracic and Cardiovascular Surgery* 2004) And, TR patients tend to be non-compliant with their medications. Thus, TR and related complications induce huge healthcare spending due to frequent re-hospitalizations. Furthermore, TR leads to chronic renal failure and end-stage dialysis. Therefore, **there is a significant unmet need for a transcatheter solution to treat TR.**

Interventional cardiologists are asking for a TTVR (Transcatheter Tricuspid Valve Repair) solution to treat patients suffering from TR and who have been considered very high-risk by the cardiac surgeon.

4Tech's TriCinch™ system is designed to be a clinically effective and cost-effective procedure to enhance the quality of life of a patient suffering from Tricuspid Valve disease. All of the major medical device companies are looking for technologies, such as TTVR, to complete their Structural Heart Disease portfolio. **TriCinch™ is the most clinically advanced TTVR system.** □

The **4Tech TriCinch™ TTVR System** is the **world's first** to reach the clinical milestone of **six months follow-up** on patients who were at "very high risk" for surgical treatment of TR, and who therefore benefited from a transcatheter repair of their Tricuspid heart valve.



We are in the midst of a changing medical landscape: from "open" surgery to transcatheter technologies for all heart valve diseases. "A vast unmet need exists for tricuspid valve repair for functional tricuspid regurgitation among patients undergoing left heart valve surgery. Once the other percutaneous technologies for mitral, aortic, or pulmonary valve become widely available, the need for percutaneous Tricuspid valve procedures will be even more apparent." **Cleveland Clinic, *Circulation*, Dec. 2009.**

What the Experts Are Saying About the Clinical Need for Transcatheter Tricuspid Valve Repair (TTVR)




Prof. Dr. Francesco Malsano
Head, Department of Cardiovascular Surgery, Zurich University Hospital Zurich, Switzerland.

"A typical TR patient has been in the chain of care for 15 years, with frequent hospitalizations. They are not candidates for TR surgery because of their frail health." (NOTE: Prof. Malsano is a co-founder of 4Tech.)



Dr. Hugo Vanermen
Cardiac Surgeon
Brussels, Belgium.

"TR greatly impacts the rate of hospitalization, inducing huge costs into the system. Surgery is very high-risk, and there is a significant unmet clinical need for a percutaneous solution." (NOTE: Dr. Vanermen is a co-founder of 4Tech.)



Dr. Azeem Latib
Interventional Cardiologist
San Raffaele Hospital
Milan, Italy

"We must develop an effective, simple device and simple procedure to restore the quality of life for patients who are suffering from Tricuspid valve disease and who are too high-risk for surgery."